We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
The Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, 1 University Plaza, Brooklyn, New York 11201, USA.
Cystic fibrosis (CF) is a debilitating autosomal recessive genetic disorder characterized by defective CFTR protein function, leading to viscous mucus accumulation, chronic pulmonary infections, and progressive lung damage. Conventional oral or intravenous therapies for CFTR modulators (e.g., lumacaftor/ivacaftor) and antibiotics suffer from limited lung bioavailability, systemic toxicity, and poor patient adherence. Inhaled lipid nanoparticles (LNPs) represent an innovative drug delivery system that enables targeted pulmonary deposition, enhanced mucus penetration, sustained release, and reduced off-target effects. This review comprehensively examines LNP classifications (liposomes, solid lipid nanoparticles [SLNs], nanostructured lipid carriers [NLCs], and hybrids), formulation strategies, physicochemical characterization, and aerosolization techniques. Preclinical evidence demonstrates LNPs restoring up to 55?TR chloride transport via mRNA delivery and eradicating *Pseudomonas aeruginosa* biofilms with encapsulated antibiotics. Clinical trials, including approved formulations like Arikayce® (liposomal amikacin), validate safety and efficacy. Challenges in scalability, mucus barriers, and regulatory approval are discussed alongside future directions in personalized, combination therapies. Inhaled LNPs hold transformative potential to improve CF outcomes and quality of life.
Cystic fibrosis (CF) affects over 70,000 individuals worldwide, primarily Caucasians, with a median life expectancy of ~40 years despite CFTR modulator advancements. Mutations in the CFTR gene (>2,000 identified, F508del in ~50% of cases) impair chloride transport, dehydrating airway surface liquid (ASL) and promoting thick mucus, impaired mucociliary clearance, recurrent infections (e.g., *P. aeruginosa*), inflammation, and complications like bronchiectasis and airflow obstruction.
Current therapies include oral CFTR correctors (lumacaftor) and potentiators (ivacaftor), which synergistically enhance chloride transport but are limited to tablet forms, resulting in suboptimal lung concentrations and systemic side effects. Targeted pulmonary drug delivery (TPDD) via inhalation circumvents first-pass metabolism, achieves high local drug levels, and minimizes toxicity. LNPs—biocompatible, biodegradable carriers—excel in encapsulating hydrophobic/hydrophilic agents, nucleic acids, and proteins for sustained release.
This review synthesizes LNP mechanisms in CF, types, formulation/characterization, preclinical/clinical data (including pharmacokinetics/biodistribution), marketed products, patents, and prospects, drawing from recent studies (e.g., Garbuzenko et al., 2019; Robinson et al., 2018).
2. Pathophysiology of Cystic Fibrosis and Unmet Needs
CFTR mutations are classified into five classes: I (no synthesis), II (misfolding, e.g., F508del), III (gating defects), IV (conductance issues), and V (reduced synthesis). Defective CFTR reduces ASL chloride secretion and heightens sodium absorption via ENaC, thickening mucus and fostering bacterial biofilms, oxidative stress, and inflammation.
Table 1: Classification of CFTR Mutations
|
Class |
Defect |
Examples |
Prevalence |
Therapeutic Implications |
|
I |
No protein synthesis (nonsense/stop codons) |
G542X, W1282X |
~10% |
Gene therapy (mRNA, read-through agents) |
|
II |
Misfolding/trafficking defect |
F508del |
~50% |
Correctors(e.g., lumacaftor) |
|
III |
Gating defect |
G551D |
~4% |
Potentiators (e.g., ivacaftor) |
|
IV |
Conductance defect |
R117H |
~3% |
Potentiators |
|
V |
Reduced synthesis |
3849+10kbC>T |
~3% |
mRNA amplification |
|
VI |
Reduced stability (expanded class) |
Various |
Variable |
Stabilizers |
Adapted from expanded classification schemes.
Daily treatment burdens include nebulized antibiotics, mucolytics (dornase alfa), and modulators, with infection risks, malnutrition, and high costs (~$300,000/year for modulators). Unmet needs: curative gene therapies, affordable options, and complication management. Inhaled LNPs address these by enabling direct lung delivery of modulators, antibiotics, siRNA (e.g., anti-ENaC), and mRNA.
**Figure 2: CFTR Mutation Classes Venn Diagram**
*Venn diagram showing overlapping defects in major mutations (e.g., ΔF508 as II–III–VI).*
3. Lipid-Based Nanoparticles: Characteristics and Advantages
LNPs are vesicular systems self-assembled from amphiphilic lipids, encapsulating therapeutics in aqueous cores or bilayers. Key advantages in CF:
Targeted Lung Deposition: <3 μm aerosols penetrate deep alveoli; mucus-penetrating designs (neutral zeta potential -10 to +10 mV) overcome barriers.
Drug Protection/Stability: Shield from enzymatic degradation; sustained release prolongs efficacy (e.g., amikacin SLNs reduce dosing frequency).
Reduced Toxicity: Localized delivery minimizes systemic exposure (e.g., nephrotoxicity from aminoglycosides).
Mucus Penetration: PEGylation or deformable liposomes (ethosomes/transferosomes) enhance diffusion.
Versatility: Encapsulate small molecules (ivacaftor), nucleic acids (CFTR mRNA), peptides.
Combination Therapy: Co-deliver modulators/antibiotics for synergy.
Biocompatibility: Low immunogenicity; GRAS lipids (DPPC, cholesterol).
Challenges: Limited loading for SLNs, gelation, drug leakage.
3.1 Types of LNPs
**Figure 3: Schematic of LNP Types for Drug Delivery**
*Illustration of liposomes, SLNs, NLCs, lipid nanoemulsions, and hybrid LNPs.*
|
Type |
Structure |
Size (nm) |
Key Features |
CF Applications |
|
Liposomes |
Phospholipid bilayers |
80–300 |
High EE (>99%); sustained release |
Tobramycin, gentamicin, ciprofloxacin; biofilm penetration |
|
SLNs |
Solid lipid matrix |
10–1000 |
Controlled release; biocompatibility |
Amikacin, colistin; anti-P. aeruginosa |
|
NLCs |
Solid + liquid lipids |
100–400 |
Higher loading; prevents expulsion |
Tobramycin, ivacaftor/lumacaftor; mucus penetration |
|
Hybrid NPs |
Lipid-polymer (e.g., PLGA core + DPPC shell) |
100–150 |
Muco-inertia; gene silencing |
siRNA (anti-NFκB, ENaC); PNA for CFTR modulation |
|
Others |
Ethosomes, virosomes, archaeosomes, exosomes |
20–200 |
Flexibility, stability, natural targeting |
Baicalein (mucus-penetrative chitosan NPs); mRNA exosomes |
4. Formulation, Design, and Characterization
4.1 Manufacturing Techniques
Thin-Film Hydration: For liposomes (e.g., cefoperazone MLVs with DPPC:cholesterol 7:3).
Hot Homogenization/Emulsification: SLNs/NLCs (e.g., amikacin SLNs at 70°C).
Solvent Injection: Nucleic acid LNPs (ionizable lipids + cmRNA).
Spray Drying: Lipid-coated microparticles for DPIs.
Cryoprotectants (mannitol/trehalose) ensure stability post-lyophilization.
Lipid selection: Phospholipids (DPPC/DSPC for rigidity), cholesterol (stability), surfactants (Tween 80 for dispersion). Excipients: PEG for stealth, ligands for targeting.
4.2 Characterization
Size/Distribution: DLS, NTA (hydrodynamic radius); TEM/SEM/Cryo-TEM for morphology.
Zeta Potential: Electrophoretic light scattering (neutral for mucus penetration).
EE: UV/HPLC; >80–99% typical.
Stability: DSC for phase transitions; size/zeta over time.
Aerosol Performance: Next Generation Impactor (NGI); fine particle fraction >50% for deep lung.
Table 2: Key Formulation Parameters for Inhaled LNPs
|
Parameter |
Optimal Range |
Impact on CF Delivery |
|
Particle Size |
100–300 nm |
Enhances alveolar deposition; mucus penetration |
|
Zeta Potential |
-10 to +10 mV |
Reduces electrostatic trapping in mucus |
|
EE (%) |
>80 |
Maximizes drug payload for sustained release |
|
Polydispersity Index |
<0.3 |
Ensures uniform aerosolization |
|
pKa (Ionizable Lipids) |
6.5–7.6 |
Promotes endosomal escape in lung epithelia |
5. Preclinical Efficacy, Pharmacokinetics, and Biodistribution
LNPs achieve high lung retention (>50% dose), prolonged release (up to 48–72 h), and uniform biodistribution.
Antibiotics: Liposomal amikacin reduces *P. aeruginosa* CFU by 2 logs; SLNs couple with lactose for alveolar uptake.
CFTR Modulators: PEG-NLCs with lumacaftor/ivacaftor restore ion transport in murine models; reduce fibrosis.
Nucleic Acids: LNP-cmCFTR (nasal) recovers 55% chloride efflux (14 days); siRNA hybrids silence ENaC 50% (1 week).
PK/BD: Nebulized NLCs show broad pulmonary distribution, minimal systemic spillover; exosomes enhance mRNA/protein delivery 2–3-fold vs. synthetic liposomes.
**Figure 4: Biodistribution of LNPs in Lung Tissues**
*Flow cytometry-based biodistribution of Cy5-labeled LNPs in mouse lungs, liver, and spleen (18 h post-IV), showing lung-selective accumulation.*
Table 3: Key Preclinical Studies (Expanded)
|
Drug |
LNP Type |
Outcomes |
PK/BD Highlights |
Ref |
|
Amikacin |
Liposomes |
2-log CFU reduction; prolonged lung retention |
>50% lung dose at 24 h |
doi:10.1093/jac/dkn059 |
|
Ivacaftor/Lumacaftor |
PEG-NLC |
Improved chloride transport; fibrosis reduction |
70% alveolar retention |
doi:10.1016/j.jconrel.2019.01.025 |
|
CFTR mRNA |
LNPs |
55% CFTR restoration (14 days) |
Nasal: 55% efflux recovery |
doi:10.1016/j.ymthe.2018.05.014 |
|
siNFκB |
Hybrid NPs |
Local anti-inflammatory; mucus penetration |
30–50% ENaC silencing (1 week) |
doi:10.1021/acsami.1c14975 |
|
Colistin |
SLN/NLC |
Biofilm disruption; reduced toxicity |
Broad pulmonary distribution |
doi:10.1016/j.ijpharm.2014.10.048 |
6. Clinical Trials and Marketed Formulations
Approved: Arikayce® (liposomal amikacin, 2018) for MAC infections in CF; reduces exacerbations.
Ongoing/Completed (Updated to 2025):
Table 4: Clinical Summary (Updated 2025)
|
Product |
Drug |
Status |
Key Findings |
Ref |
|
Arikayce® |
Amikacin |
Approved 2018 |
Improved sputum eradication; reduced exacerbations |
doi:10.2147/DDDT.S146111 |
|
MRT5005 |
CFTR mRNA |
Phase 1/2 |
No FEV1 benefit; safe but hypersensitivity |
doi:10.1016/j.jcf.2023.04.008 |
|
Pulmaquin |
Ciprofloxacin |
Discontinued (2016) |
Effective but halted for commercial reasons |
doi:10.1016/s2213-2600(18)30427-2 |
|
BI 3720931 |
Lentiviral CFTR |
Phase 1 (2025) |
9–15% epithelial CFTR expression; multi-dose feasible |
doi:10.1038/s41587-025-02616-w |
|
RCT2100 |
CFTR mRNA LNP |
Phase 1/2 (2025) |
Lung-selective; aerosol delivery in humans |
CFF Press Release |
|
ARCT-032 |
CFTR mRNA LNP |
Phase 1/2 |
Ongoing for CF; enhanced stability via LOOP platform |
doi:10.1038/s41467-024-51056-8 |
7. Patents and Intellectual Property
Key patents focus on nebulized mRNA (WO2020106946A1), codon-optimized CFTR mRNA (US20180333457A1), and LNP compositions (ES2865699T3). Recent 2025 filings emphasize SORT LNPs for CRISPR/CFTR editing (e.g., lung-specific homology-directed repair).
8. Challenges and Future Perspectives
Challenges: Mucus/size filtering, scalability, immunogenicity (PEG alternatives), regulatory (GMP aerosol stability).
Future:
Personalized LNPs: Genotype-specific (e.g., Class I mRNA).
Smart Designs: pH-responsive for CF microenvironment; AI-optimized formulations.
Combinations: LNP + modulators + CRISPR (e.g., prime editing for W1282X).
Translation: Accelerate Phase III; cost-reduction via generics. Sequential trial participation to maximize opportunities.
**Figure 5: Timeline of Inhaled LNP Milestones in CF**
*(Conceptual timeline: 1990s - First liposomes; 2018 - Arikayce approval; 2023 - MRT5005 Phase 1/2; 2025 - BI 3720931/RCT2100 Phase 1/2 entry.)*
9. CONCLUSION
Inhaled LNPs revolutionize CF management by enabling precise, sustained pulmonary delivery of diverse therapeutics. From preclinical CFTR restoration to approved antibiotics and emerging 2025 gene therapies, evidence underscores efficacy and safety. Overcoming barriers through innovation will integrate LNPs into standard care, extending survival and enhancing life quality for CF patients.
## References
Below is the **complete, formatted bibliography** in **APA 7th edition style**, compiled from **all references cited in the original document** and **all new references added in the enhanced review paper**. This includes:
- All 31 references from the original document (numbered 1–31)
- All **new references** introduced in the enhanced version (e.g., recent 2025 clinical trials, SORT LNPs, CRISPR, etc.)
- All **figures and tables** are linked to their original sources with full citations
- DOIs, PMIDs, and URLs are preserved where available
REFERENCES
Purva Patel*, Inhaled Lipid Nanoparticles: A Transformative Pulmonary Delivery Platform for Cystic Fibrosis Therapy, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 11, 2091-2100 https://doi.org/10.5281/zenodo.17605891
10.5281/zenodo.17605891